{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:29:22Z","timestamp":1793212162216,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer Canada Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with increasing evidence of effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there are scarce prospective data analyzing the efficacy and rapidity of action in hospitalized ASUC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The TRIUMPH study is a prospective open-label interventional trial of tofacitinib in hospitalized patients with ASUC conducted in 5 hospitals across Canada (Clinicaltrials.gov: NCT04925973). Eligible participants included biologic-na\u00efve and experienced patients with ASUC refractory to 3 days of intravenous (IV) corticosteroids (Modified Truelove-Witts Severity Index [MTWSI]\u2005&amp;gt;\u200510 despite steroids). Participants were treated with tofacitinib 10\u00a0mg twice daily and assessed daily while in hospital. The primary outcome was day 7 clinical response (MTWSI reduction of\u2005&amp;gt;\u20053 from baseline and \u2264 10).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 24 subjects, 33.3% (8\/24) had previous anti-TNF failure. Day 7 clinical response was achieved in 58.3% (14\/24). The mean number of days to achieve clinical response was 2.4 (SD 1.3). Marked reduction in C-reactive protein was observed in responders within the first two days after tofacitinib initiation compared to nonresponders. Colectomy occurred in 25% (6\/24) by 6 months, with no additional colectomy beyond this time point. Five participants reported a total of 13 adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tofacitinib is an effective rescue therapy in hospitalized patients with steroid-refractory ASUC. Randomized controlled trials are warranted to compare JAK inhibitors with other rescue therapies, including infliximab in steroid-refractory ASUC (Clinicaltrials.gov: NCT04925973).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otaf013","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T12:43:21Z","timestamp":1739623401000},"source":"Crossref","is-referenced-by-count":12,"title":["Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9244-8235","authenticated-orcid":false,"given":"Cara","family":"Pray","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6999-3125","authenticated-orcid":false,"given":"Hasan","family":"Hamam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-3192","authenticated-orcid":false,"given":"Farhad","family":"Peerani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta Hospital , Edmonton, AB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawnya","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology,\u00a0Health Sciences Centre\/University of Manitoba , Winnipeg, MB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-1910","authenticated-orcid":false,"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McGill University Health Center , Montreal, QC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-8209","authenticated-orcid":false,"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology,\u00a0St. Paul\u2019s Hospital\/University of British Colombia , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arathi","family":"Arun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Schmit","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology,\u00a0St. Paul\u2019s Hospital\/University of British Colombia , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Castelli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-5457","authenticated-orcid":false,"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre , Hamilton, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"4","key":"2025031406421904200_CIT0001","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025031406421904200_CIT0002","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ajg.2011.386","article-title":"Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements","volume":"107","author":"Bitton","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"11","key":"2025031406421904200_CIT0003","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","article-title":"Acute severe ulcerative colitis: from pathophysiology to clinical management","volume":"13","author":"Hindryckx","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"9857","key":"2025031406421904200_CIT0004","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet."},{"issue":"1","key":"2025031406421904200_CIT0005","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2025031406421904200_CIT0006","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025031406421904200_CIT0007","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2025031406421904200_CIT0008","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"18","key":"2025031406421904200_CIT0009","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"7","key":"2025031406421904200_CIT0010","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial: Tofacitinib in ASUC","volume":"119","author":"Singh","year":"2022","journal-title":"Off J Am Coll Gastroenterol| ACG"},{"key":"2025031406421904200_CIT0011","article-title":"Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2","author":"Hanauer","year":"2018"},{"key":"2025031406421904200_CIT0012","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2014.04.057","article-title":"Statistical comparison of the slopes of two regression lines: a tutorial","volume":"838","author":"Andrade","year":"2014","journal-title":"Anal Chim Acta."},{"issue":"12","key":"2025031406421904200_CIT0013","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1016\/j.cgh.2022.02.055","article-title":"Corticosteroids and mesalamine versus corticosteroids for acute severe ulcerative colitis: a randomized controlled trial","volume":"20","author":"Ben-Horin","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"Supplement_1","key":"2025031406421904200_CIT0014","doi-asserted-by":"publisher","first-page":"i1611","DOI":"10.1093\/ecco-jcc\/jjad212.1002","article-title":"P872 PREDICT UC: optimising infliximab induction therapy for acute severe ulcerative colitis \u2013 a randomised controlled trial","volume":"18","author":"Choy","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025031406421904200_CIT0015","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"2025031406421904200_CIT0016","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metabol Disposit."},{"issue":"5","key":"2025031406421904200_CIT0017","doi-asserted-by":"publisher","first-page":"297","DOI":"10.5414\/cpp48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"2","key":"2025031406421904200_CIT0018","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2025031406421904200_CIT0019","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2025031406421904200_CIT0020","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci."},{"issue":"1","key":"2025031406421904200_CIT0021","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","article-title":"Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program","volume":"29","author":"Lichtenstein","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025031406421904200_CIT0022","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacol Therap."},{"issue":"8","key":"2025031406421904200_CIT0023","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaf013\/61902960\/otaf013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/1\/otaf013\/61902960\/otaf013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/1\/otaf013\/61902960\/otaf013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T06:42:36Z","timestamp":1741934556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaf013\/8016062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaf013","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,30]]},"article-number":"otaf013"}}